BAMOMAB

Human **soluble MICA ELISA** Kit

Antigen:	**Soluble human MICA (MHC-class I-related chain A)**
Catalog Number:	MICA-EK-1000
Applications:	Detection of soluble MICA in serum and cell culture supernatants
Capture antibody (1 vial):	
Clone:	AMO1 (mouse IgG1, kappa)
Concentration:	1 mg/ml
Formulation:	0.5 mg in 0.5 ml phosphate-buffered saline, pH 7.4, no sodium azide
Storage:	Store at 4°C. For long-term storage freezing at -20°C is recommended.
Detection antibody (1 vial):	
Clone:	BAMO3 (mouse IgG2a, kappa)
Concentration:	0.2 mg/ml
Formulation:	0.1 mg in 0.5 ml phosphate-buffered saline, pH 7.4, no sodium azide
Storage:	Store at 4°C. For long-term storage freezing at -20°C is recommended.
Standard (5 vials):	recombinant soluble MICA*04 (purified from E.coli)
Concentration:	100 ng/ml
Formulation:	20 ng in 0.2 ml phosphate-buffered saline, 5% bovine serum albumin, pH 7.4
Storage:	Store at -20°C. Use aliquots after thawing within 1-2 weeks.
Usage:	See attached ELISA instruction sheet.

Description:

MICA (MHC class I-related chain A) is a polymorphic, human MHC-encoded cell surface glycoprotein and ligand of the activating C-type lectin-like immunoreceptor NKG2D [1-5]. NKG2D engagement of MICA activates NK cells and costimulates CD8 T cells [3,6]. MICA is expressed on gastrointestinal epithelium and inducible by cell stress, viral and bacterial infection [2,6-8]. MICA is also expressed by malignant epithelial and haematopoietic cells, and MICA expression has been shown to enhance tumor rejection in vivo [9-12]. Tumor cells shed soluble MICA which is detectable in sera of patients with epithelial and haematopoietic malignancies and may counteract tumor immunosurveillance [10,13-15].

Conditions:

For research use only. Not for use in diagnostic or therapeutic procedures. BAMOMAB is not responsible for any patent infringements caused by the use of this product.

Country of Origin: Germany

Literature:

1. Bahram S et al. *Proc Natl Acad Sci USA* **91**, 6259-6263 (1994).
2. Groh V et al. *Proc Natl Acad Sci USA* **93**, 12445-12450 (1996).
3. Bauer S et al. *Science* **285**, 727-729 (1999).
4. Steinle A et al. *Immunogenetics* **53**, 279-287 (2001).
5. Li P et al. *Nat Immunol* **2**, 443-451 (2001).
6. Groh V et al. *Nat Immunol* **2**, 255-260 (2001).
7. Spies T *Proc Natl Acad Sci USA* **99**, 2584-2586 (2002).
8. Welte S et al. *Eur J Immunol* **33**, 194-203 (2003).
9. Groh V et al. *Proc Natl Acad Sci USA* **96**, 6879-6884 (1999).
10. Salih HR et al. *Blood* **102,** 1389-1396 (2003).
11. Friese MA et al. *Cancer Res* **63**, 8996-9006 (2003).
12. Wiemann K et al. *J Immunol* **175**, 720-729 (2005).
13. Salih HR et al. *J Immunol* **169**, 4098-4102 (2002).
14. Groh V et al. *Nature* **419**, 734-738 (2002).
15. Holdenrieder S et al. *Int J Cancer* **118**, 684-687 (2006).

BAMOMAB GmbH, Habsburgerstrasse 5, 80801 Munich, Germany.
Fax ++49-(0)89-3303-7335 www.bamomab.com order@bamomab.com